Sialic acid binding ig-like lectin 15
| SIGLEC15 | |||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Identifiers | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Aliases | SIGLEC15, CD33L3, HsT1361, SIGLEC-15, Sialic acid binding ig-like lectin 15, sialic acid binding Ig like lectin 15 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| External IDs | OMIM: 618105 MGI: 3646642 HomoloGene: 52643 GeneCards: SIGLEC15 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
| Wikidata | |||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||
Sialic acid binding Ig-like lectin 15 (Siglec-15) is a protein that in humans is encoded by the SIGLEC15 gene.[5] Siglec-15 is predominately expressed on osteoclasts, elevated levels of Siglec- 15 in the bone metastatic niche can promote tumor-induced osteoclastogenesis as well as suppress antigen-specific T cell responses. Researchers demonstrated that antibody blockade of the Siglec-15/sialic acid glycol-immune checkpoint axis can act as a potential treatment for breast cancer bone metastasis.[6]
References[edit]
- ^ a b c GRCh38: Ensembl release 89: ENSG00000197046 – Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000091055 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Entrez Gene: Sialic acid binding Ig-like lectin 15".
- ^ "Siglec-15/sialic acid axis as a central glyco-immune checkpoint in breast cancer bone metastasis".
Further reading[edit]
- Yixian W, Zhan X, Kuan-Lin W (January 2024). "Siglec-15/sialic acid axis as a central glyco-immune checkpoint in breast cancer bone metastasis". Proceedings of the National Academy of Sciences. 121 (5): e2312929121. doi:10.1073/pnas.2312929121. PMID 38252825.
- Takamiya R, Ohtsubo K, Takamatsu S, Taniguchi N, Angata T (February 2013). "The interaction between Siglec-15 and tumor-associated sialyl-Tn antigen enhances TGF-β secretion from monocytes/macrophages through the DAP12-Syk pathway". Glycobiology. 23 (2): 178–87. doi:10.1093/glycob/cws139. PMID 23035012.
- Angata T, Tabuchi Y, Nakamura K, Nakamura M (August 2007). "Siglec-15: an immune system Siglec conserved throughout vertebrate evolution". Glycobiology. 17 (8): 838–46. doi:10.1093/glycob/cwm049. PMID 17483134.
 | This article on a gene on human chromosome 18 is a stub. You can help Wikipedia by expanding it. |